Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15279029 | 0.86 | KMT2A (0.41) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL9915426 | 0.78 | MAPT (0.50) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL9915312 | 0.74 | ALDH1A1 (0.47) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL9915308 | 0.72 | CYP1A2 (0.38) | TSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL9632462 | 0.71 | RAB9A (0.61) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL15923220 | 0.69 | MAPT (0.62) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL8298007 | 0.69 | RAB9A (0.79) | RAB9AHPGDNPC1L3MBTL1NPSR1 | |
| SCHEMBL30036364 | 0.69 | KMT2A (0.46) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL15924331 | 0.69 | RAB9A (0.58) | RAB9AHPGDTSHRNPC1MAPK1 | |
| SCHEMBL15922820 | 0.69 | RAB9A (0.59) | RAB9AHPGDTSHRNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | RAB9A 2614/4885HPGD 2345/4885TSHR 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.